These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8208006)

  • 1. [Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation].
    López J; Cancelas JA; Valiño JM; García-Laraña J; Sastre JL; Pérez-Oteyza J; Cerveró C; García-Avello A; Cabezudo E; Arranz MI
    Med Clin (Barc); 1994 Apr; 102(13):485-8. PubMed ID: 8208006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
    Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.
    van der Jagt RH; Pari G; McDiarmid SA; Boisvert DM; Huebsch LB
    Bone Marrow Transplant; 1994 Feb; 13(2):203-7. PubMed ID: 8205090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
    Stockschläder M; Kalhs P; Peters S; Zeller W; Krüger W; Kabisch H; Lechner K; Zander A
    Bone Marrow Transplant; 1993 Oct; 12(4):357-62. PubMed ID: 8275035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
    Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
    Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation.
    Bianco JA; Appelbaum FR; Nemunaitis J; Almgren J; Andrews F; Kettner P; Shields A; Singer JW
    Blood; 1991 Sep; 78(5):1205-11. PubMed ID: 1878587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
    Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
    Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
    Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Charlet JP; Schlaifer D; Huynh A; Laurent G; Pris J
    Blood; 1993 Aug; 82(3):732-6. PubMed ID: 8338943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience.
    Bacigalupo A; Zikos P; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Mordini N; Bregante S; Berisso G; Vitale V; Sessarego M; Marmont AM
    Exp Hematol; 1998 May; 26(5):409-14. PubMed ID: 9590657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
    Madero L; Díaz MA; Ortega JJ; Olive T; Martínez A; Badell I; Muñoz A; Gómez P
    Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.